ADME investigations of novel therapeutic modalities: challenges and opportunities 2025

20260 citationsJournal Article

Authors

Hongbin Yu · Boehringer Ingelheim (Taiwan)

Richard Dambra · Boehringer Ingelheim (Taiwan)

Gary Chan · Boehringer Ingelheim (Taiwan)

Elise Ishida · Boehringer Ingelheim (Taiwan)

Ali Khalilimeybodi · Boehringer Ingelheim (Taiwan)

Nicholas Krebs · Boehringer Ingelheim (United States)

Minu Ravindra Pilvanker

Abstract

By integrating recent preclinical and clinical insights with advances in bioanalytical methods and mechanistic modeling, we present forward-looking perspectives on enabling more precise and effective dosing strategies for these complex modalities.

Topics & Keywords

Publication Details

Published in: Expert Opinion on Drug Metabolism & Toxicology

DOI: 10.1080/17425255.2026.2650189

Field-Weighted Citation Impact: 0.00

Command Palette

ADME investigations of novel therapeutic modalities: challenges and opportunities 2025

Authors

Abstract

Topics & Keywords

Publication Details